264 related articles for article (PubMed ID: 20161752)
1. Telomere shortening sensitizes cancer cells to selected cytotoxic agents: in vitro and in vivo studies and putative mechanisms.
Uziel O; Beery E; Dronichev V; Samocha K; Gryaznov S; Weiss L; Slavin S; Kushnir M; Nordenberg Y; Rabinowitz C; Rinkevich B; Zehavi T; Lahav M
PLoS One; 2010 Feb; 5(2):e9132. PubMed ID: 20161752
[TBL] [Abstract][Full Text] [Related]
2. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma.
Djojosubroto MW; Chin AC; Go N; Schaetzlein S; Manns MP; Gryaznov S; Harley CB; Rudolph KL
Hepatology; 2005 Nov; 42(5):1127-36. PubMed ID: 16114043
[TBL] [Abstract][Full Text] [Related]
3. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.
Frink RE; Peyton M; Schiller JH; Gazdar AF; Shay JW; Minna JD
Oncotarget; 2016 May; 7(22):31639-51. PubMed ID: 27192120
[TBL] [Abstract][Full Text] [Related]
4. Thymoquinone induces telomere shortening, DNA damage and apoptosis in human glioblastoma cells.
Gurung RL; Lim SN; Khaw AK; Soon JF; Shenoy K; Mohamed Ali S; Jayapal M; Sethu S; Baskar R; Hande MP
PLoS One; 2010 Aug; 5(8):e12124. PubMed ID: 20711342
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics of telomerase inhibition and telomere shortening by noncytotoxic suramin.
Gan Y; Lu J; Yeung BZ; Cottage CT; Wientjes MG; Au JL
AAPS J; 2015 Jan; 17(1):268-76. PubMed ID: 25425294
[TBL] [Abstract][Full Text] [Related]
6. The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function.
Burger AM; Dai F; Schultes CM; Reszka AP; Moore MJ; Double JA; Neidle S
Cancer Res; 2005 Feb; 65(4):1489-96. PubMed ID: 15735037
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib-mediated down-regulation of telomerase and disruption of telomere homeostasis contributes to apoptosis of malignant cells.
Ci X; Li B; Ma X; Kong F; Zheng C; Björkholm M; Jia J; Xu D
Oncotarget; 2015 Nov; 6(35):38079-92. PubMed ID: 26472030
[TBL] [Abstract][Full Text] [Related]
8. A Cisplatin Derivative Tetra-Pt(bpy) as an Oncotherapeutic Agent for Targeting ALT Cancer.
Zheng XH; Nie X; Fang Y; Zhang Z; Xiao Y; Mao Z; Liu H; Ren J; Wang F; Xia L; Huang J; Zhao Y
J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28521363
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of telomerase activity in endometrial cancer cells by selenium-cisplatin conjugate despite suppression of its DNA-damaging activity by sodium ascorbate.
Błasiak J; Kadłubek M; Kowalik J; Romanowicz-Makowska H; Pertyński T
Teratog Carcinog Mutagen; 2002; 22(1):73-82. PubMed ID: 11754389
[TBL] [Abstract][Full Text] [Related]
10. Senescence and telomere shortening induced by novel potent G-quadruplex interactive agents, quindoline derivatives, in human cancer cell lines.
Zhou JM; Zhu XF; Lu YJ; Deng R; Huang ZS; Mei YP; Wang Y; Huang WL; Liu ZC; Gu LQ; Zeng YX
Oncogene; 2006 Jan; 25(4):503-11. PubMed ID: 16170347
[TBL] [Abstract][Full Text] [Related]
11. Combined treatment with emodin and a telomerase inhibitor induces significant telomere damage/dysfunction and cell death.
Liu R; Liu J; Wang S; Wang Y; Zhang T; Liu Y; Geng X; Wang F
Cell Death Dis; 2019 Jul; 10(7):527. PubMed ID: 31296842
[TBL] [Abstract][Full Text] [Related]
12. Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor.
Hu Y; Bobb D; Lu Y; He J; Dome JS
Cancer Genet; 2014 Sep; 207(9):403-11. PubMed ID: 25441685
[TBL] [Abstract][Full Text] [Related]
13. How to inhibit telomerase activity for cancer therapy.
Kyo S; Inoue M
Curr Med Chem Anticancer Agents; 2002 Sep; 2(5):613-26. PubMed ID: 12678728
[TBL] [Abstract][Full Text] [Related]
14. Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2'-deoxyguanosine.
Mender I; Gryaznov S; Dikmen ZG; Wright WE; Shay JW
Cancer Discov; 2015 Jan; 5(1):82-95. PubMed ID: 25516420
[TBL] [Abstract][Full Text] [Related]
15. Silencing PinX1 compromises telomere length maintenance as well as tumorigenicity in telomerase-positive human cancer cells.
Zhang B; Bai YX; Ma HH; Feng F; Jin R; Wang ZL; Lin J; Sun SP; Yang P; Wang XX; Huang PT; Huang CF; Peng Y; Chen YC; Kung HF; Huang JJ
Cancer Res; 2009 Jan; 69(1):75-83. PubMed ID: 19117989
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Novel Schizocommunin Derivatives as Telomeric G-Quadruplex Ligands That Trigger Telomere Dysfunction and the Deoxyribonucleic Acid (DNA) Damage Response.
Che T; Chen SB; Tu JL; Wang B; Wang YQ; Zhang Y; Wang J; Wang ZQ; Zhang ZP; Ou TM; Zhao Y; Tan JH; Huang ZS
J Med Chem; 2018 Apr; 61(8):3436-3453. PubMed ID: 29618208
[TBL] [Abstract][Full Text] [Related]
17. Telomerase inhibition is a specific early event in salvicine-treated human lung adenocarcinoma A549 cells.
Liu WJ; Zhang YW; Shen Y; Jiang JF; Miao ZH; Ding J
Biochem Biophys Res Commun; 2004 Oct; 323(2):660-7. PubMed ID: 15369801
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach.
Mo Y; Gan Y; Song S; Johnston J; Xiao X; Wientjes MG; Au JL
Cancer Res; 2003 Feb; 63(3):579-85. PubMed ID: 12566299
[TBL] [Abstract][Full Text] [Related]
19. G-quadruplex stabilizer Tetra-Pt(bpy) disrupts telomere maintenance and impairs FAK-mediated migration of telomerase-positive cells.
Shen Z; Zheng R; Yang H; Xing S; Jin X; Yan H; Zhu J; Mei Y; Lin F; Zheng X
Int J Biol Macromol; 2022 Jul; 213():858-870. PubMed ID: 35697164
[TBL] [Abstract][Full Text] [Related]
20. Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors.
Mueller S; Hartmann U; Mayer F; Balabanov S; Hartmann JT; Brummendorf TH; Bokemeyer C
Invest New Drugs; 2007 Dec; 25(6):519-24. PubMed ID: 17534576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
